Items where Author is "Hunt, David"

ABDO, Hafez, MANGENA, Musa, NEEDHAM, Graham and HUNT, David (2017). Provisions for Oil and Gas Decommissioning Costs: Compliance with Disclosure Requirements by Oil and Gas Companies Listed in the UK. In: International Conference on Accounting Studies (ICAS) 2017, 18 Sep 2017 - 20 Sep 2017. ICAS. [Conference or Workshop Item]

BRITTAIN, Gavin, PETRIE, Jennifer, DUFFY, Kate E. M., GLOVER, Rachel, HULLOCK, Katie, PAPAIOANNOU, Diana, ROLDAN, Elisa, BEECHER, Colette, BURSNALL, Matthew, CICCARELLI, Olga, COLES, Alasdair J., COOPER, Cindy, GIOVANNONI, Gavin, GABRIEL, Ian, KAZMI, Majid, KYRIAKOU, Charalampia, NICHOLAS, Richard, PALING, David, PENIKET, Andy, SCOLDING, Neil, SILBER, Eli, DE SILVA, Thushan, VENNERI, Annalena, WALTERS, Stephen J., YOUNG, Carolyn, MURARO, Paolo A., SHARRACK, Basil, SNOWDEN, John A., PUBLICOVER, Amy, CLARK, Andy, BEN TURNER, Caroline Besley, KYRIAKOU, Charalampia, CRAWLEY, Charles, RICE, Claire, HUNT, David, ROG, David, THOLOULI, Eleni, NIKFEKR, Esmaeil, KINSELLA, Fran, LUCA, Gabriele De, MAZIBRADA, Gordon, HUNTER, Hannah, POMEROY, Ian, DAVIES, Jeff, BYRNE, Jenny, HOBART, Jeremy, CAMPBELL, Keith, ORCHARD, Kim, FINISKU, Leonora, DUDDY, Martin, VINJAM, Maruthi, SAIF, Muhammad, ROBERTSON, Neil, CICCARELLI, Olga, GALLAGHER, Paul, BULLEY, Simon, CAMPBELL, Vic and ISMAIL, Azza (2024). Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial. BMJ Open, 14 (2). [Article]

ABDO, Hafez, MANGENA, Musa, NEEDHAM, Graham and HUNT, David (2018). Disclosure of provisions for decommissioning costs in annual reports of oil and gas companies: A content analysis and stakeholder views. Accounting Forum. [Article]